Given the individual trials were small can't we garner a little extra credibility from the fact that there were actually three trials using chemo incombination that were structured similarly and they all showed signicant efficacy. Also, doesn't the fact that the overall MOA appears to be working in viral as well as cancer which would seem to further validate the smaller trial samples when viewed in their totality.
Are you talking about investing or what the FDA considers significant entdoc? I think that is the reason all of us are here. The priliminary data is good. Sure it's been shown to be safe and yes the data is strong enough to further the trials. That is the case in all drugs that move on. Very few are accepted though. Not knocking Bavi, just not getting overzealous at this point. The lack of any acknowledged interest at this point is bothersome. Sorry, I no longer put much stock in Kings "We're in talks" after the Stason announcement.
News 
Market Data 
Discover 
AI
